Susquehanna International Group’s Apogee Therapeutics APGE Stock Holding History

Susquehanna International Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.38M	Buy	111,500 +69,800	+167%	+$5.07M	﹤0.01%	3212
2025 Q4	$3.15M	Sell	41,700 -37,900	-48%	-$2.39M	﹤0.01%	4801
2025 Q3	$3.16M	Sell	79,600 -73,100	-48%	-$2.79M	﹤0.01%	4873
2025 Q2	$6.63M	Buy	152,700 +63,400	+71%	+$2.41M	﹤0.01%	3484
2025 Q1	$3.34M	Buy	89,300 +36,100	+68%	+$1.4M	﹤0.01%	4436
2024 Q4	$2.41M	Buy	53,200 +44,300	+498%	+$2.26M	﹤0.01%	4888
2024 Q3	$523K	Buy	8,900 +100	+1%	+$4.79K	﹤0.01%	8362
2024 Q2	$346K	Buy	+8,800	New	+$427K	﹤0.01%	9134

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Susquehanna International Group's APGE Position: Q1 2026 in Review

Susquehanna International Group increased its Apogee Therapeutics (APGE) stake by 247% in Q1 2026, buying an estimated $833K and bringing the position to 16,099 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #7143.

Susquehanna International Group first reported a position in APGE in Q4 2023 and has held it in 10 quarters since. The position peaked at $3.03M in Q3 2024. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Susquehanna International Group held 16,099 shares of Apogee Therapeutics worth $1.36M as of Q1 2026.
Susquehanna International Group bought 11,465 Apogee Therapeutics shares in Q1 2026, an estimated $833K.
Apogee Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7143 holding.
Susquehanna International Group first reported a position in Apogee Therapeutics in Q4 2023 and has held it in 10 quarters since.
Susquehanna International Group's Apogee Therapeutics position peaked at $3.03M in Q3 2024.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.